Stay Alert for Safety Issues With Janus Kinase Inhibitors (Xeljanz, etc)

Questions will pop up about the safety of Janus kinase (JAK) inhibitors...Xeljanz, Olumiant, and the newly approved Rinvoq.

There's an uptick in use of JAK inhibitors for rheumatoid arthritis and other autoimmune diseases...because they're oral.

But these specialty meds may fly under your radar if patients don't fill them at your pharmacy.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote